Apricus Biosciences Inc (NASDAQ:APRI) has been downgraded to Sell in a statement by Zacks Investment Research earlier today.
- Updated: October 12, 2016
Showing a price of $0.33, Apricus Biosciences Inc (NASDAQ:APRI) traded -5.71% lower on the day. With the last stock price close down -20.22% from the 200-day average, compared with the S&P 500 Index which has decreased -0.01% over the same time period. APRI has recorded a 50-day average of $0.36 and a two hundred day average of $0.41. 316,305 shares of the stock were exchanged, down from an average trading volume of 758,716
Zacks Investment Research has downgraded Apricus Biosciences Inc (NASDAQ:APRI) to Sell in a statement released on 10/12/2016.
On 8/6/2015, Roth Capital released a statement on Apricus Biosciences Inc (NASDAQ:APRI) dropped the target price from $4.00 to $3.00 that suggested an upside of 1.46%.
See Chart Below
Apricus Biosciences Inc has a 52 week low of $0.28 and a one year high of $1.64 APRI’s total market value is presently $0.
More About Apricus Biosciences Inc (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.